Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer

June 20, 2019 updated by: Chandra P. Belani, Milton S. Hershey Medical Center

Phase I/II Study of Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer

This is a phase I/II study. The phase I portion of the study will determine the maximum tolerated dose of bortezomib when administered in combination with carboplatin & docetaxel and to determine the efficacy of the combination for patients with advanced NSCLC. Phase II will utilize the dosage determined in the Phase I and implement regimen to determine time to progression, overall survival, and changes in serum proteomics patterns before & after combination therapy.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

A chemotherapy efficacy plateau' has been reached for the treatment of patients with advanced or metastatic non-small cell lung cancer. Platinum-based two-drug combination is considered the current standard of care for the treatment of advanced NSCLC. There is a need to develop novel regimens to improve the outcome for patients with advanced NSCLC. The combination of carboplatin and docetaxel is effective for therapy of advanced NSCLC. This combination results in improved survival and quality of life for patients with advanced NSCLC. Docetaxel exhibits preclinical synergy with bortezomib.

The trial was intended to be a phase I/II study to define the maximum tolerated dose of bortezomib that can be administered in combination with docetaxel and carboplatin and subsequently evaluate the efficacy of the regimen for patients with advanced NSCLC. However, the trial never moved past the phase I portion of the study and was terminated early.

Study Type

Interventional

Enrollment (Actual)

6

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Pennsylvania
      • Hershey, Pennsylvania, United States, 17033
        • Penn State College of Medicine, Penn State Milton S. Hershey Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Histologically/cytologically confirmed stage IIIB (pleural or pericardial effusion) or stage IV NSCLC
  • Age > 18 years
  • ECOG PS < 2
  • No prior chemotherapy
  • Measurable disease
  • Signed informed consent
  • Adequate bone marrow function
  • Adequate renal function
  • Adequate hepatic function

Exclusion Criteria:

  • Untreated clinically active brain metastasis
  • Radiotherapy within 2 weeks prior to initiation of protocol therapy
  • Treatment with any investigational therapy within 4 weeks prior to enrollment
  • History of any cancer other than NSCLC (except non-melanoma skin cancer or carcinoma on situ of the cervix) within the last 5 years
  • Patients in their reproductive age group should use an effective method of birth control. Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter. Patients who are breast-feeding will be excluded from the study. Women of childbearing potential must have a negative pregnancy test.
  • Major surgery within 3 weeks prior to enrollment
  • Use of immunosuppressive agents including systemic corticosteroids within 4 weeks prior to enrollment (corticosteroids are permitted as physiological replacement therapy or as supportive care for nausea and emesis)
  • Known history of Human immunodeficiency virus infection
  • Any co-morbidity or condition of sufficient severity to limit full compliance with the protocol per assessment by the investigator
  • Concurrent serious medical infection or illness, or psychiatric illness likely to interfere with participation in this clinical study.
  • History of known hypersensitivity to docetaxel or other drugs formulated with polysorbate 80, bortezomib, boron or mannitol
  • Patient has Grade 2 peripheral neuropathy within 14 days before enrollment.
  • Myocardial infarction within 6 months prior to enrollment or has New York Hospital Association (NYHA) Class III or IV heart failure (see section 8.4), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Phase I - Dose Level 1
Carboplatin AUC 5 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)
Drug: Bortezomib
Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
Other Names:
  • PS-341
  • VELCADE
Drug: Carboplatin
Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
Other Names:
  • Paraplatin
Drug: Docetaxel
Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
Other Names:
  • Taxotere
Experimental: Phase I - Dose Level 2A
Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)
Drug: Bortezomib
Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
Other Names:
  • PS-341
  • VELCADE
Drug: Carboplatin
Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
Other Names:
  • Paraplatin
Drug: Docetaxel
Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
Other Names:
  • Taxotere
Experimental: Phase I - Dose Level 2B
Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)
Drug: Bortezomib
Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
Other Names:
  • PS-341
  • VELCADE
Drug: Carboplatin
Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
Other Names:
  • Paraplatin
Drug: Docetaxel
Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
Other Names:
  • Taxotere
Experimental: Phase I - Dose Level 3
Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)
Drug: Bortezomib
Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
Other Names:
  • PS-341
  • VELCADE
Drug: Carboplatin
Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
Other Names:
  • Paraplatin
Drug: Docetaxel
Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
Other Names:
  • Taxotere
Experimental: Phase I - Dose Level 4
Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 75 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)
Drug: Bortezomib
Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
Other Names:
  • PS-341
  • VELCADE
Drug: Carboplatin
Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
Other Names:
  • Paraplatin
Drug: Docetaxel
Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
Other Names:
  • Taxotere
Experimental: Phase I - Dose Level 5
Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 75 mg/m2 (Day 1) Bortezomib 1.3 mg/m2 (Day 1,4,8,11)
Drug: Bortezomib
Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
Other Names:
  • PS-341
  • VELCADE
Drug: Carboplatin
Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
Other Names:
  • Paraplatin
Drug: Docetaxel
Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
Other Names:
  • Taxotere
Experimental: Phase II
Carboplatin AUC 5 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)
Drug: Bortezomib
Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
Other Names:
  • PS-341
  • VELCADE
Drug: Carboplatin
Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
Other Names:
  • Paraplatin
Drug: Docetaxel
Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
Other Names:
  • Taxotere

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Determine maximum tolerated dose of bortezomib when administered in combination with carboplatin & docetaxel for treatment of patients with advanced NSCLC cancer. Determine the response rate of the combination for patients with advanced NSCLC.
Time Frame: Expected average of 2 years
Expected average of 2 years

Secondary Outcome Measures

Outcome Measure
Time Frame
Define dose-limiting toxicities of the combination of carboplatin, docetaxel & bortezomib for patients with advanced NSCLC. Determine the time to progression & overall survival, assess toxicities, determine changes in serum proteomics patterns
Time Frame: Expected average of 2 years
Expected average of 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Milton S. Hershey Medical Center

Collaborators

Sanofi

Investigators

  • Principal Investigator: Chandra P. Belani, MD, Penn State College of Medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2008

Primary Completion (Actual)

May 1, 2013

Study Completion (Actual)

May 1, 2013

Study Registration Dates

First Submitted

July 7, 2008

First Submitted That Met QC Criteria

July 10, 2008

First Posted (Estimate)

July 14, 2008

Study Record Updates

Last Update Posted (Actual)

June 24, 2019

Last Update Submitted That Met QC Criteria

June 20, 2019

Last Verified

June 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PSU 26983

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe